Fisetin for Improving Vascular Function in Older Adults: A Phase II Clinical Trial

• Age 65 years or older
• Women must be postmenopausal
• Body mass index (BMI) \<40 kg/m2
• Willing to accept random assignment
• Weight stable in the prior 2 months (\<2 kg weight change) and willing to remain weight stable throughout the study
• Ability to understand study procedures and to comply with them for the entire length of the study
• Absence of established, serious, unstable, chronic clinical disease (e.g., unstable cardiovascular disease) that would make it unsafe for the individual to participate in the trial as determined by trial physician of record.

Exclusion Criteria:

• Inability to refrain from alcohol for 24 hours prior to outcome assessment, alcohol dependence or abuse
• Individuals taking fisetin, quercetin, luteolin, Dasatinib, piperlongumine or Navitoclax (supplements or drugs with possible senolytic effects) within 6 months prior to baseline testing as reported during medication review during screening. Should new research reveal other dietary supplements or drugs with potential senolytic effects, their use will be evaluated, and their use may lead to exclusion of the participant by the principal investigator (PI)
• New use of regular cardiovascular-acting medication which, in the opinion of the PI, affects the outcomes of the study within 3 months prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 3 months of regular use)
• Chronic use of a dietary supplement which, in the opinion of the PI, affects the outcomes of the study, within 1 month prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 1 month of regular use)
• Active malignancy (including myeloma) or malignancy that was active within 5 years prior to baseline testing as reported during Medical History and Physical and/or on study screening forms
• Inability or unwillingness of individual to give written informed consent
• Current or past participation within 3 months in another clinical trial that, in the opinion of the PI, would affect the outcomes of the study
• Blood donation within 8 weeks prior to baseline testing; unwillingness to abstain from blood donation during the study and for 8 weeks after study completion
• Resting blood pressure >160 mmHg systolic or >100 mmHg diastolic.
• Regular vigorous aerobic/endurance exercise (>6 bouts/week at a moderate-high intensity)